Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Lupin Limited    LUPIN   INE326A01037

End-of-day quote. End-of-day quote  - 10/18
1053.9 INR   -1.14%
10/13 LUPIN : Acquires Symbiomix Therapeutics LLC
10/11 LUPIN : Acquires Symbiomix Therapeutics LLC
09/01 LUPIN : launches generic Fosrenol Chewable Tablets in the US
News SummaryMost relevantAll newsSector newsTweets

Lupin Limited : Lupin Looking for Acquisitions of up to $500 Million in US

share with twitter share with LinkedIn share with facebook
share via e-mail
08/01/2012 | 12:39pm CEST

--Looking for buys in skin care, eye care, respiratory and women's health products

--Trying to expand pipeline of low-competition generic drugs for US market

(Adds executive's comments in 7th, 9th, 12th and 13th paragraphs, background and context elsewhere)

By Rumman Ahmed

BANGALORE--Lupin Ltd. (500257.BY) is looking to aggressively grow its business in the U.S. and is scouting for acquisitions of pharmaceutical brands and manufacturers, and seeking regulatory approval to sell a wider range of niche generic drugs.

The U.S. is Lupin's primary growth market, accounting for 35% of its sales.

The India drug maker is benefiting from a wave of patent expiries for popular drugs in the U.S. But to keep the business momentum going once the "patent cliff" wave wanes, Lupin is looking to acquire branded products that are much bigger that its previous purchases.

"We've looked at small-sized acquisition opportunities as well as opportunities in the $400 million-$500 million price range," group president Vineeta Gupta recently told Dow Jones Newswires.

Unlike most of its local rivals, Lupin's business model for the world's largest pharmaceuticals market is not limited to selling drug copies: It also sells branded products like antibiotic Suprax and anti-cholesterol drug Antara. While the branded products contribute about 25% of Lupin's U.S. revenue, they make up a larger share of its profit.

Lupin is looking for acquisitions to revive the momentum in the branded-products business at a time when existing brands are likely to come up against generic competition.

The company would prefer acquisitions in the areas of skin care, eye care, respiratory and women's health products, which are more in line with the company's commercial infrastructure in the U.S., Ms. Gupta said.

The company's 160-person sales force in the U.S. is focused on selling branded products to the pediatric and primary-care market segments.

Ms. Gupta, who also heads Lupin's U.S. unit, said Lupin had mulled acquiring eye-care company ISTA Pharmaceuticals Inc., but found it wasn't a "good fit."

Eye-products maker Bausch & Lomb Inc. purchased ISTA for about $500 million in cash in a deal that closed in June.

Lupin's previous acquisitions in the U.S. were much smaller in comparison. In 2009 it paid $38.61 million to bankrupt Oscient Pharmaceuticals Corp. for Antara, and acquired AllerNaze nasal spray from U.S.-based Collegium Pharmaceutical Inc. for an undisclosed amount.

As for its generic drugs business, Lupin is trying to move its pipeline to products that are exclusive and face less competition, Ms. Gupta said.

Lupin has already applied to sell generic versions of about 31 oral contraceptive products and some eye treatments. It has also filed the first generic drug application with the U.S. regulator for a skin care product in the January-March period, she added.

Benefits from selling these drugs, which have relatively high entry barriers and offer higher-than-average margins, are expected to kick in from the fiscal year starting next April.

Write to Rumman Ahmed at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on LUPIN LIMITED
10/13 LUPIN : Acquires Symbiomix Therapeutics LLC
10/11 LUPIN : Acquires Symbiomix Therapeutics LLC
10/10 LUPIN : launches generic Norco Tablets in the US
09/22 LUPIN : Next two years will pose challenges for lupin in us
09/14 LUPIN : receives USFDA approval for generic Flagyl tablets
09/13 LUPIN : Taps external funding for r&d of biosimilars
09/12 LUPIN : receives final approval for Vibra-Tabs tablets
09/11 LUPIN : receives final approval for Vibra-Tabs tablets
09/05 LUPIN : launches generic hypertension drug in US market
09/05 LUPIN : S generic hypertension drug
More news
Financials ( INR)
Sales 2018 168 B
EBIT 2018 28 366 M
Net income 2018 19 741 M
Debt 2018 44 058 M
Yield 2018 0,71%
P/E ratio 2018 24,27
P/E ratio 2019 18,28
EV / Sales 2018 3,09x
EV / Sales 2019 2,65x
Capitalization 475 B
Duration : Period :
Lupin Limited Technical Analysis Chart | LUPIN | INE326A01037 | 4-Traders
Technical analysis trends LUPIN LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 41
Average target price 1 121  INR
Spread / Average Target 6,7%
EPS Revisions
Nilesh Deshbandhu Gupta Managing Director & Executive Director
Vinita D. Gupta Chief Executive Officer & Executive Director
Manju Deshbandu Gupta Chairman
Ramesh Swaminathan Chief Financial Officer & Executive Director
Alok Ghosh President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
LUPIN LIMITED-28.96%7 303
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116